Make Informed Investment Decisions with Affordable Access to Experts
Discussing the current treatment landscape for AML (Vyxeos, Idhifa/Tibsovo) and where Venclexta could fit in after recently gaining FDA accelerated approvalTicker(s): JAZZ, RHHBY, ABBV, AGIO
Name: Dr Gabriel Ghiaur - MD
Institution: Johns Hopkins University
- Medical oncologist affiliated with the Sidney Kimmel Comprehensive Cancer Center and an assistant professor at Johns Hopkins University.
- Currently manages 80-100 patients per year with AML; sees 50 new patients a year out of 300 in his group.
- Physician-scientist whose primary interest is normal and malignant hematopoiesis; research has translational potential in stem cell therapeutics, as well as acute leukemia.
Please describe your clinical practice; roughly how many patients with AML do you currently manage?Added By: c_admin
Have you prescribed Jazz Pharma's Vyxeos and/or Agios’ Idhifa/Tibsovo?Added By: c_admin
What are your thoughts on the FLT3 inhibitors (midostaurin and gilteritinib)? When do you test for FLT3 mutations and where do you see them best fitting into the treatment plan (maintenance? relapse?).Added By: thealchemist
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.